CFTR and cystic fibrosis: In summary, genotype/phenotype correlations among individuals with mild or atypical CF, and recent clinical data using the FDA approved potentiator of CFTR gating (ivacaftor/KalydecoTM), indicate that modest enhancement of F508del CFTR processing by as little as 3-fold above lumacaftor alone may be sufficient to offer substantial benefit to individuals homozygous for F508del [18].